Overview


Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is used to treat inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. The medication is usually prescribed for patients who have mild to moderately severe illnesses. Both tablets and capsules are available for oral or rectal administration. Oral formulations appear to be equal. There are many side effects that can occur, such as headaches, nausea, pain in the abdomen, fever, ache, nausea, abdominal pain, and fever. A number of serious side effects may occur, including pericarditis, liver damage, and kidney damage. It appears that the use of this product during pregnancy and breastfeeding is safe. Formulations that contain sulfa may be problematic for those suffering from a sulfa allergy. In addition to being a constituent of aminosalicylates, mesalazine is an anti-inflammatory drug. Direct contact with the intestines is what makes it work. There are several types of inflammatory bowel diseases that can be treated with mesalazine, including ulcerative colitis and Crohn's disease. The medicine belongs to a class of medicines called aminosalicylates. Reduces redness (inflammation) and swelling (redness) and can help promote healing. The combination of mesalazine and steroids is sometimes used by some people. It works differently in different parts of your gut depending on the brand of mesalazine tablet or granule you use. In order to treat lower intestinal problems, people are prescribed rectal foam, suppositories, and enemas. The best thing to do is to stick with the same brand of mesalazine after you and your doctor find one that works for you. Once you have your symptoms under control, you can usually reduce your dosage. The most common side effects of mesalazine are stomach upset and muscle aches and pains. It is possible to experience problems with your blood as a very rare side effect. Symptoms of illness, such as bleeding, bruising, red or purple marks on the skin, a sore throat, high temperature, or a general feeling of being unwell, need to be reported to your doctor immediately.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Mesalazine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Mesalazine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
• Ferring
• Allergan
• Lunan Better Pharmaceutical
• Sandoz Mesalamine
• Nogra Pharma
• Mylan
• Synmosa Biopharma Corporation
• Cipla
• Teva
• Janssen (Johnson and Johnson)
• Dr Falk Pharma
• Chiesi Farmaceutici
• Abbvie
• Boehringer Ingelheim
• Pfizer
• Shanghai Sine Promod Pharmaceutical
• Tillotts Pharma
• Takeda
• Salix Pharmaceuticals
• AstraZeneca
• Cosmo Pharmaceuticals
(Note: The list of the major players will be updated with the latest market scenario and trends)
By Type
• Oral Intake
• Rectum Intake
By Application
• Ulcerative Colitis
• Crohn's Disease
• Others
By Region
North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
• To provide with an exhaustive analysis on the Mesalazine Market By Type, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Mesalazine Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Mesalazine Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Mesalazine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Mesalazine Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Oral Intake
        2. Rectum Intake
  • 8.   Mesalazine Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Ulcerative Colitis
        2. Crohn's Disease
        3. Others
  • 9.   North America Mesalazine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 10.   Latin America Mesalazine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 11.   Europe Mesalazine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 12.   Asia Pacific Mesalazine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 13.   Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ferring
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Lunan Better Pharmaceutical
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sandoz Mesalamine
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Nogra Pharma
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Mylan
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Synmosa Biopharma Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Cipla
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Teva
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Janssen (Johnson and Johnson)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Dr Falk Pharma
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        12.Chiesi Farmaceutici
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13.Abbvie
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14.Boehringer Ingelheim
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15.Pfizer
         1. Company Overview
         2. Product Portfolio
         3. SWOT Analysis
         4. Financial Overview
         5. Strategic Overview
        16.Shanghai Sine Promod Pharmaceutical
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17.Tillotts Pharma
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18.Takeda
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19.Salix Pharmaceuticals
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20.AstraZeneca
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21.Cosmo Pharmaceuticals
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients